A phase 3 study of vepdegestrant in combination with a CDK4/6 inhibitor in a second-line Breast Cancer
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Vepdegestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 16 Jan 2025 New trial record
- 10 Jan 2025 According to Arvinas media release, this trial is planned to initiate in 2025.